Efficacy observation of gemcitabine and isosfamide in treatment of refractory breast cancer

Objective To evaluate the efficacy of gemcitabine and isosfamide in the treatment of refractory breast cancer.Methods Gemcitabine 1 000 mg/m2 was intravenously infused for 30 min,once a week for three weeks,then taking rest for a week,repeated every four weeks,the dose was correspondingly reduced according to adverse reactions.Isosfamide 1.5 g/m2 was taken by intravenous drip on 1,5 d.Cisplatinum 25-30 mg/m2 was given by intrvenous drip on 1,3 d.Mesna,each dose was equivalent to 20% of the amount of isosfamide,was given by intravenous drip at 0,4,8 h during isosfamide intravenous drip.30 d was a chemotherapeutic cycle.Each patient completed at least two chemotherapeutic cycles and the treatment effects were evaluatied.The observation group took the treatment scheme of gemcitabine and isosfamide and the control group received the treatment scheme of gemcitabine and cisplatinum.Results Among 74 cases in the observation group,3 cases were CR,17 cases were PR,28 cases were SD,26 cases were PD,the effective rate was 27.03%(20/74) and the clinical control rate was 64.86%(48/74),which showed no statistical difference compared with the control group(P0.05).The adverse reactions in the observation group were neutropenia(77.03%,57/74),thrombocytopenia(58.11%,43/74),abnormal hemoglobin(31.08%,23/74),nausea and vomiting(27.03%,20/74),diarrhea(33.78%,25/74),liver function damage(28.38%,21/74),hand-foot syndrome(20.27%,15/74).The adverse reactions were dominated by Ⅰ~Ⅱdegree,which were improved after symptomatic treatment.No case in two groups discontinued chemotherapy due to adverse reactions and no treatment-related death occurred.The chemotherapy was tolerable.Conclusion Gemcitabine plus isosfamide is satisfactory in the treatment of refractory breast cancer.